Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk’s Wegovy oral weight-loss drug.
Trending
- Starmer crisis deepens with resignations over Mandelson-Epstein links
- Trump threatens to block opening of new bridge between US and Canada
- 49ers’ Keion White Shot In San Francisco After Super Bowl, Non-Life Threatening Injury
- Meta Goes to Trial in a New Mexico Child Safety Case. Here’s What’s at Stake
- Plane makes emergency landing in Gainesville, Georgia, strikes vehicles
- Trump threatens to block US-Canada bridge over trade dispute
- Lindsey Vonn needs ‘multiple surgeries’ after Olympic crash : NPR
- George Briner, The Valory Music Co. President, to Retire
Tuesday, February 10
Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor
